Aridis Pharmaceuticals Inc Revenue Growth Rates (ARDS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aridis Pharmaceuticals Inc   (NASDAQ: ARDS)
 

ARDS's Revenue Growth by Quarter and Year

Aridis Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARDS Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 0.42
2nd Quarter June 19.65
1st Quarter March 1.08
FY 21.15

ARDSs Annual Revenue
Aridis Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 3.09 millions
Aridis Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 1.54 millions
Aridis Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 1.00 millions
Aridis Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 1.02 millions
Aridis Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 0.86 millions




ARDS Revenue third quarter 2023 Y/Y Growth Comment
Aridis Pharmaceuticals Inc reported Revenue growth of 4.25% year on year in the third quarter 2023, to $ 0.42 millions, this is lower than Aridis Pharmaceuticals Inc 's recent average Revenue surge of 1044.66%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue growth. While Aridis Pharmaceuticals Inc ' s Revenue increase of 4.25% ranks overall at the positon no. 2223 in the third quarter 2023.


ARDS Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 22.22 % - -
3rd Quarter September 4.25 % -23.08 % - -
2nd Quarter June 6675.86 % 866.67 % -97 % -
1st Quarter March -9.24 % - - -
FY   - 100.65 % 54 % -

Financial Statements
Aridis Pharmaceuticals Inc 's third quarter 2023 Revenue $ 0.42 millions ARDS's Income Statement
Aridis Pharmaceuticals Inc 's third quarter 2022 Revenue $ 0.40 millions Quarterly ARDS's Income Statement


ARDS Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 202.5 % 90.38 % -
3rd Quarter September -97.88 % 37.93 % 1633.33 % -
2nd Quarter June 1719.44 % -75.63 % - -
1st Quarter March -10.74 % 20.2 % - -
FY (Year on Year)   - 100.65 % 54 % -


Back to ARDS Growth rate Comparisons >> Back to ARDS Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #319
Overall #2223

Revenue Y/Y Growth Statistics
High Average Low
6628.42 % 1044.66 % -96.7 %
(Mar 31 2023)   (Sep 30 2023)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #319
Overall #2223
Revenue Y/Y Growth Statistics
High Average Low
6628.42 % 1044.66 % -96.7 %
(Mar 31 2023)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Aridis Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1460.61 % 203.37 % -100 %
(Sep 30 2021)  


ARDS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Aridis Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -97.88% to $ 0.42 millions, from $ 19.65 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 232 other companies have achieved higher Revenue quarter on quarter growth. While Aridis Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3689.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #233
Healthcare Sector #605
Overall #3689
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #233
Healthcare Sector #605
Overall #3689
Revenue Q/Q Growth Statistics
High Average Low
1460.61 % 203.37 % -100 %
(Sep 30 2021)  


ARDS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Aridis Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -97.88% to $ 0.42 millions, from $ 19.65 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 232 other companies have achieved higher Revenue quarter on quarter growth. While Aridis Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3689.


Aridis Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 22.36 $ 22.34 $ 2.99 $ 3.09 $ 2.87
Y / Y Revenue Growth (TTM) 680.42 % 649.45 % 9.7 % - -
Year on Year Revenue Growth Overall Ranking # 2157 # 0 # 1708 # 0 # 0
Seqeuential Revenue Change (TTM) 0.08 % 648.19 % -3.4 % 7.89 % -3.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 3205 # 0 # 1768 # 0 # 2179


Cumulative Revenue growth Comment
With 680.42% annual Revenue growth, Aridis Pharmaceuticals Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.

In the Healthcare sector 286 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2157.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 287
Overall # 2157

Revenue TTM Y/Y Growth Statistics
High Average Low
680.42 %
 446.52 %
9.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 170
Sector # 438
S&P 500 # 3205
Cumulative Revenue growth Comment
With 680.42% annual Revenue growth, Aridis Pharmaceuticals Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.

In the Healthcare sector 286 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2157.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 287
Overall # 2157

Revenue TTM Y/Y Growth Statistics
High Average Low
680.42 %
446.52 %
9.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 170
Sector # 438
S&P 500 # 3205




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARDS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Collegium Pharmaceutical Inc 7.32%$ 7.321 millions
Accuray Incorporated7.25%$ 7.254 millions
Chemed Corporation7.23%$ 7.229 millions
Encision Inc 7.16%$ 7.160 millions
Teva Pharmaceutical Industries Limited7.09%$ 7.093 millions
Aspira Women s Health inc 7.00%$ 6.998 millions
Option Care Health Inc 6.99%$ 6.989 millions
Keenova Therapeutics Plc6.95%$ 6.954 millions
Bausch and Lomb Corp6.90%$ 6.900 millions
Universal Health Services Inc 6.80%$ 6.797 millions
Agenus Inc6.77%$ 6.771 millions
Merck and Co Inc 6.70%$ 6.705 millions
Labcorp Holdings Inc 6.63%$ 6.628 millions
Innovage Holding Corp 6.58%$ 6.580 millions
National Healthcare Corp6.51%$ 6.514 millions
Sonida Senior Living Inc 6.40%$ 6.396 millions
Vertex Pharmaceuticals Inc6.39%$ 6.392 millions
Adapthealth Corp 6.28%$ 6.284 millions
Tactile Systems Technology Inc 6.28%$ 6.278 millions
Select Medical Holdings Corp6.24%$ 6.244 millions
Cytosorbents Corporation6.11%$ 6.109 millions
Meiragtx Holdings Plc5.96%$ 5.959 millions
Biorestorative Therapies Inc 5.86%$ 5.862 millions
Davita Inc 5.85%$ 5.855 millions
Sotera Health Company5.74%$ 5.742 millions
American Shared Hospital Services5.68%$ 5.675 millions
Staar Surgical Co5.60%$ 5.605 millions
Tenet Healthcare Corp5.52%$ 5.520 millions
Nature s Sunshine Products inc 5.48%$ 5.485 millions
Inspiremd Inc 5.27%$ 5.271 millions


About Aridis Pharmaceuticals Inc Revenue Growth Rates (ARDS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aridis Pharmaceuticals Inc (CIK 1614067).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-23-039521
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aridis Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.